Company profile
Australis Capital Inc.
OTC: AUSAF · Healthcare · Drug Manufacturers - Specialty & Generic
#690 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
——FH —DQ —GM —SS 28
v0.1 · 5/100 weight · pillars only
↑ 3-yr revenue growth, revenue growth (YoY) · ↓ Altman-Z, market scale
Methodology →Revenue TTM
$5.1M
Rev growth YoY (TTM)
+2529.8%
Net income (FY)
-$40.0M
Employees
18
as of 2026-08-30
Market cap
$2.8k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$6.0M7.6M CAD2021
Net income-$40.0M-50.1M CAD2021
Operating income-$15.5M-19.4M CAD2021
Total assets$40.5M50.6M CAD2021
Liabilities$11.3M14.2M CAD2021
Equity$16.8M20.9M CAD2021
Revenue trend
FY2016 – FY2021 · USD
FY16
FY17
FY18
FY19
FY20
FY21
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Australis Capital Inc.’s revenue?
Australis Capital Inc. booked $6.0M in FY2021 revenue, growing 1014% year over year — faster than 96% of Healthcare companies we track, at a -661.5% net margin.
Peers · Healthcare
bioAffinity Technologies, Inc.32DOracle Healthcare Acquisition Corp.——Bloomios, Inc.——Lancer Orthodontics, Inc.——Abeona Therapeutics Inc.69BMPX International Corp.——Neighbors
Clark →Key facts
CEOTerrance R. Booth
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersLas Vegas, NV
ExchangeOTC: AUSAF
Employees18
IPO date2018-09-28
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.